TN-001

TN-001
Clinical data
Other namesTN001
Routes of
administration		Unspecified[1]
Drug classSerotonin receptor modulator; Non-hallucinogenic serotonin 5-HT2A receptor agonist; Psychoplastogen

TN-001 is a non-hallucinogenic psychoplastogen which is under development for the treatment of major depressive disorder and post-traumatic stress disorder (PTSD).[1][2][3][4] Its route of administration is unspecified.[1] The drug acts as a serotonin receptor modulator, including as a serotonin 5-HT2A receptor partial agonist and serotonin 5-HT2B receptor antagonist, and is said to produce psychoplastogenic effects.[1][2][3][4] It is being developed by Transneural Therapeutics, a spinout of CaaMTech.[1][2][4] As of June 2025, TN-001 is in the preclinical research stage of development.[1][2][3] A clinical trial is being planned.[1] The chemical structure of the drug does not yet appear to have been disclosed.[1]

See also

References

  1. ^ a b c d e f g h "TN 001". AdisInsight. 4 June 2025. Retrieved 24 October 2025.
  2. ^ a b c d "Delving into the Latest Updates on TN-001 with Synapse". Synapse. 8 May 2025. Retrieved 19 May 2025.
  3. ^ a b c "Transneural Therapeutics". The Pharmaletter. 7 May 2025. Retrieved 19 May 2025.
  4. ^ a b c Kuntz L (23 April 2025). "Transneural Therapeutics: A New Company to Develop Novel Neuroplastogens". Psychiatric Times. Retrieved 19 May 2025.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.